-
PublishedJuly 6, 2023
FDA gives full approval for Alzheimer’s drug Leqembi, and Medicare will pay for it
The Food and Drug Administration endorsed the IV drug, Leqembi, for patients with mild dementia and other symptoms caused by early Alzheimer's disease.
-
PublishedFebruary 1, 2023
Sen. Collins spearheads efforts to fund Alzheimer’s research
A bipartisan group of senators is proposing to boost funding for research and prevention through 2035.
-
PublishedJanuary 6, 2023
FDA approves Alzheimer’s drug that modestly slows disease
The drug, Leqembi, is the first that’s been convincingly shown to slow the decline in memory and thinking that defines Alzheimer’s by targeting the disease's underlying biology.
-
PublishedNovember 29, 2022
Drug slows Alzheimer’s but can it make a real difference?
New data shows an experimental Alzheimer's drug modestly slowed the brain disease's inevitable worsening.
-
PublishedOctober 13, 2022
Maine Voices: The long goodbye – my family, my father and Alzheimer’s
The disease’s progression tests our ties, but maybe a cure is in the pipeline so other families will not have to endure what we and many millions of others do each day.
-
PublishedSeptember 28, 2022
Gov. Mills launches program to give grants up to $2,000 to family caregivers
The $5.1 million program is for family caregivers of patients with disabilities, such as Alzheimer's and dementia, who are being cared for at home.
-
PublishedAugust 2, 2022
Even simple exercise may help aging brain, study hints
Stretching and balancing moves can be as beneficial as an aerobic workout.
-
PublishedNovember 13, 2021
Commentary: The next hospital crisis is coming. Let’s hope the U.S. is prepared
Response teams that respect and protect patients and care providers are one essential solution for behavioral emergencies among people with dementia.
-
PublishedJuly 29, 2021
Research looks for possible COVID-19 link to later Alzheimer’s
Experts stress far more research is needed – and getting underway – to tell if COVID-19 might raise the risk of Alzheimer's or other brain problems later in life, or if people eventually recover from 'brain fog.'
-
PublishedJuly 9, 2021
FDA chief calls for investigation into review of controversial new Alzheimer’s drug
It's the latest fallout over last month's approval of Aduhelm, an expensive and unproven therapy that the agency OK'd against the advice of its own outside experts.
- 1
- 2
- 3
- Next Page →